( 1) Framingham Heart
|
|
- Harold McKinney
- 5 years ago
- Views:
Transcription
1 ( 1) ( 1) Framingham Heart Study [1] 1. (Am J Kidney Dis. 45: , 2005)
2 Framingham Heart Study ( 1) American Heart Association (1) (2) (3) (4) [2] (GFR) [3] ARIC [4] Cardiovascular Health Study [5] Hoorn study [6] (GFR) GFR [7] NHANES II Mortality Study GFR 70 ml/min [8] GFR Aspirin beta blocker Angiotensionconverting enzyme (ACE) inhibitor (microalbuminuria) K/DOQI guidelines mg 3 mg/dl mg/g 1. (Homocysteine) Lipoprotein(a) and apolipoprotein(a) isoforms LDL Lipoprotein remnants (C-reactive protein) (malnutrition) Thrombogenic factors Nitric oxide/endothelin Am J Kidney Dis. 45: ,
3 mg/g [9] ( 2) (sarcomeres) eccentric hypertrophy ( 45%) concentric hypertrophy ( 45%) 30% stage 3 4 [10] 55% GFR 59 ml/min [11] [12] ARIC stage 3 low GFR [13] 2. (Kidney Int 68: , 2005)
4 (artherosclerotic plaque) (collagen) (arteriosclerosis) arterial stiffening stage 5 53% ( 50% ) [14] (inflammation) (oxidative stress) (hyperhomocysteinemia) (metabolic syndrome) (abnormal calcium and phosphate metabolism) (endothelial cell dysfunction and injury) 1. (inflammation) C (C-reactive protein) CRP MDRD CRP Interleukin-6 Interleukin-10 tumor necrosis factor (TNF) receptor I and II TNF-α fibrinogen [15-16] 2. (oxidative stress) (reactive oxygen species, ROS) (proinflammatory cytokine) [17] (insulin resistance) [18] (Lipid peroxidation products plasma F2-isoprostanes, malonyldialdehyde) advanced oxidation protein products (LDL) reduced glutathione E Heart Outcomes and Protection (HOPE) E [19] Secondary Prevention with Antioxidants of Cardiovascular Disease in End- Stage Renal Disease(SPACE) E [20] 3. (metabolic syndrome) 2005 (International Diabetes Federation) mg/dl 40 mg/dl 50 mg/dl 100 mg/dl 130/85 mmhg adiponectin adiponectin adiponectin [21] hypoadiponectinemia [22] 4. (hyperhomocysteinemia)
5 [23] (Homocysteine) GFR [24] stage 3 4 GFR [25] B6 B12 [26] 5. ( e n d o t h e l i a l c e l l dysfunction and injury) brachial artery reactivity Aymmetric dimethylarginine (ADMA) ADMA ADMA [27] ADMA left ventricular mass index [28] ADMA ADMA 1. Wilson PW, D Agostino RB, Levy D, et al: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: Appel LJ: Beyond (or back to) traditional risk factors: Preventing cardiovascular disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: Go AS, Chertow GM, Fan D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: Manjunath G, Tighiouart H, Ibrahim H, et al: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J AmColl Cardiol 2003; 41: Fried LF, Shlipak MG, Crump C, et al: Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41: Henry RM, Kostense PJ, Bos G, et al: Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: Weiner DE, Tighiouart H, Amin MG, et al: Chronic kidney disease as a risk factor for cardiovascular disease and allcause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: Wachtell K, Ibsen H, Olsen MH, et al: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Intern Med 2003; 139: Mcmahon LP, Roger SD, Levin A: Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J AmSoc Nephrol 2004; 15: Mcalister FA, Ezekowitz J, Tonelli M, et al: Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: Levin A, Singer J, Thompson CR, et al: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996; 27: Astor BC, Arnett DK, Brown A, et al: Association of kidney function and hemoglobin with left ventricular morphology among African Americans: The Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2004; 43: Ohtake T, et al: High Prevalence of Occult Coronary Artery Stenosis in Patients with Chronic Kidney Disease at the Initiation of Renal Replacement Therapy: An Angiographic Examination. J Am Soc Nephrol 2005; 9: Menon V, Greene T, Wang X, et al: C-reactive protein and serum albumin as predictors of all-cause and cardiovascular mortality in patients with chronic kidney disease. Kidney Int 2005; 68: Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al: Advanced oxidation protein products as risk factors
6 for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45: Gordon CA, Himmelfarb J: Antioxidant therapy in uremia: Evidence-based medicine? Semin Dial 2004; 17: Himmelfarb J, Stenvinkel P, Ikizler TA, et al: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: Mann JF, Lonn EM, Yi Q, et al: Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 2004; 65: Boaz M, Smetana S,Weinstein T, et al: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 2000; 356: Zoccali C, Mallamaci F, Tripepi G, et al: Adiponectin, metabolic risk factors, and cardiovascular events among patients with endstage renal disease. J AmSoc Nephrol 2002; 13: Iwashima Y, Ogihara T, et al: Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol Dec 15; 98(12): Epub 2006 Oct Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998; 338: Mallamaci F, Zoccal C, Tripepi G, et al: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: Menon V, Sarnak MJ, Greene T, et al: Relationship between homocysteine and mortality in chronic kidney disease. Circulation 2006; 113: Wrone EM, Hornberger JM, Zehnder JL, et al: Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J AmSoc Nephrol 2004; 15: Valkonen VP, Paiva H, Salonen JT, et al: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: Zoccali C, Mallamaci F, Maas R, et al: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62:
Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationDesigned to be taken at facility only 3 times per week. Greater convenience for patients & caregivers and compliance for providers
MV-ONE PLUS is a novel antioxidative nutraceutical especially formulated for patients with chronic kidney disease (CKD). MV-ONE PLUS has been designed as a supplement to address vitamin D deficiency and
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationCAD in Chronic Kidney Disease. Kuang-Te Wang
CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,
More information10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
More informationCardiovascular Risk Among Adults With Chronic Kidney Disease, With or Without Prior Myocardial Infarction
Journal of the American College of Cardiology Vol. 48, No. 6, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.05.047
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationJOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationMicroalbuminuria As Predictor Of Severity Of Coronary Artery Disease In Non-Diabetic Patients:
ISPUB.COM The Internet Journal of Cardiology Volume 9 Number 1 Microalbuminuria As Predictor Of Severity Of Coronary Artery Disease In Non-Diabetic Patients: F Aziz, S Penupolu, S Doddi, A Alok, S Pervaiz,
More informationAssociation between Renal Insufficiency and Inducible Ischemia in Patients with Coronary Artery Disease: The Heart and Soul Study
J Am Soc Nephrol 14: 3233 3238, 2003 Association between Renal Insufficiency and Inducible Ischemia in Patients with Coronary Artery Disease: The Heart and Soul Study JOACHIM H. IX,* MICHAEL G. SHLIPAK,*
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationGlomerular Filtration Rate, Albuminuria, and Risk of Cardiovascular and All-Cause Mortality in the US Population
American Journal of Epidemiology ª The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.
More informationNumerous epidemiologic studies have shown an association
SYMPOSIUM ARTICLE Cardiorenal Risk Factors Barry M. Wall, MD Abstract: The chronic renocardiac syndrome, in which chronic kidney disease (CKD) contributes to impairment of cardiac function or structure,
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationCHRONIC KIDNEY DISEASE (CKD) is a
Cardiovascular Outcomes and All-Cause Mortality: Exploring the Interaction Between CKD and Cardiovascular Disease Daniel E. Weiner, MD, MS, Sayed Tabatabai, MD, Hocine Tighiouart, MS, Essam Elsayed, MD,
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationDietary practices in patients with chronic kidney disease not yet on maintenance dialysis: What are the relevant components?
Dietary practices in patients with chronic kidney disease not yet on maintenance dialysis: What are the relevant components? 3 rd International Conference of European Renal Nutrition Working Group of ERA-EDTA
More informationElizabeth Wrone, MD Clinical Instructor Stanford University School of Medicine Associate Director of Research Satellite Health Care, Inc
Nutritional Interventions to Reduce Cardiovascular Risk in Chronic Renal Failure February 24, 2001 Elizabeth Wrone, MD Clinical Instructor Stanford University School of Medicine Associate Director of Research
More informationScreening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!
Screening for chronic kidney disease racial implications Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications 1) Definition of CKD 2) Why should we screen
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationSympathetic nervous system and NO in CKD. Francesca Mallamaci
Sympathetic nervous system and NO in CKD Francesca Mallamaci Go AS, New Engl J Med. 351: 1296; 24 1.12.295 individuals, follow up 2.8 yea risk factors peculiar to CKD Old age Relative Risk (fully independent)
More informationInflammation in Renal Disease
Inflammation in Renal Disease Donald G. Vidt, MD Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-crp) levels have been
More informationChronic Kidney Disease: Everything that you need to know!
: Everything that you need to know! Matthew R. Weir, MD Professor and Director Division of Nephrology University of Maryland School of Medicine Baltimore, Maryland Overview CKD and CVD Blood Pressure Lipids
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationDo Associations With C-Reactive Protein and Extent of Coronary Artery Disease Account for the Increased Cardiovascular Risk of Renal Insufficiency?
Journal of the American College of Cardiology Vol. 42, No. 1, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00564-3
More informationEvaluation of Plasma Concentrations of Homocysteine, IL-6, TNF-alpha, hs- CRP, and Total Antioxidant Capacity in Patients with End-Stage Renal Failure
ORIGINAL ARTICLE Evaluation of Plasma Concentrations of Homocysteine, IL-6, TNF-alpha, hs- CRP, and Total Antioxidant Capacity in Patients with End-Stage Renal Failure Mahin Babaei 1, Nasrin Dashti 2,
More informationSerum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease
Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular
More informationAsymmetric dimethylarginine (ADMA) is an endogenous
Kidney International, Vol. 68 (2005), pp. 2230 2236 Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell
More informationFunctional Blood Chemistry & CBC Analysis
Functional Blood Chemistry & CBC Analysis Session 10 Inflammation Markers The 19 Deadly Sins of Heart Disease 1. Excess LDL 2. Excess Total cholesterol 3. Low HDL 4. Excess Triglycerides 5. Oxidized LDL
More informationPatients with chronic kidney disease (CKD) are
CLINICAL INTERVENTIONS TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH KIDNEY DISEASE Jeffrey S. Berns, MD* ABSTRACT Although the specific mechanisms by which chronic kidney disease (CKD) and cardiovascular
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationCardiovascular disease (CVD) is the leading cause of morbidity
Effects of Anemia and Left Ventricular Hypertrophy on Cardiovascular Disease in Patients with Chronic Kidney Disease Daniel E. Weiner,* Hocine Tighiouart, Panagiotis T. Vlagopoulos,* John L. Griffith,
More informationTraditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective
RENAL INSUFFICIENCY: AN EPIDEMIOLOGIC OVERVIEW Since much of the issues discussed in this review pertain to the risk of disease (be it renal or cardiovascular), it is useful to review the concept of risk
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationBeta-blockers for coronary heart disease in chronic kidney disease
Nephrol Dial Transplant (2008) 23: 2274 2279 doi: 10.1093/ndt/gfm950 Advance Access publication 10 January 2008 Original Article Beta-blockers for coronary heart disease in chronic kidney disease Michel
More informationModern Medical Laboratory Journal - ISSN X
Original Article Mod Med Lab. 2017; 1(1): 17-17 22 Modern Medical Laboratory Journal - ISSN 2371-770X An Investigation of the Relationship between Beta-2 Microglobulin (β2m) and Inflammatory Factors (Serum
More informationChronic Kidney Disease is Associated with Cognitive Decline: the Northern Manhattan Study (NOMAS) Seattle VA Chief of Medicine Rounds June 9, 2009
Chronic Kidney Disease is Associated with Cognitive Decline: the Northern Manhattan Study (NOMAS) Seattle VA Chief of Medicine Rounds June 9, 2009 Minesh Khatri Internal Medicine R2 Background Patients
More informationORIGINAL INVESTIGATION. Cross-Classification of Microalbuminuria and Reduced Glomerular Filtration Rate
ORIGINAL INVESTIGATION Cross-Classification of Microalbuminuria and Glomerular Filtration Rate Associations Between Cardiovascular Disease Risk Factors and Clinical Outcomes Meredith C. Foster, BA; Shih-Jen
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationEstimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease
Journal of Cardiology (2009) 53, 232 239 ORIGINAL ARTICLE Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease Keita Matsuo (MD),
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationTHE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS
214 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 21(3):23-212 doi: 1.2478/rjdnmd-214-25 THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationCardiovascular disease (CVD) is the leading cause of
Cardiovascular Disease in Early Stages of Chronic Kidney Disease in a Chinese Population LuXia Zhang,* Li Zuo,* Fang Wang,* Mei Wang,* ShuYu Wang, JiCheng Lv,* LiSheng Liu, and HaiYan Wang* *Institute
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients
More informationThe incidence and prevalence of hypertension
Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004 Madhav V. Rao, MD, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 and George
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationLong-term outcomes in nondiabetic chronic kidney disease
original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationCardiovascular disease (CVD) is the leading
CORE CURRICULUM IN NEPHROLOGY Cardiovascular Disease and CKD: Core Curriculum 2010 Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD).
More informationIntravenous Iron Does Not Affect the Rate of Decline of Residual Renal Function in Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 22, 2006 Hemal Shah, Ashutosh Shukla, Abirami Krishnan, Theodore Pliakogiannis, Mufazzal Ahmad, Joanne M. Bargman, Dimitrios G. Oreopoulos Intravenous Iron Does Not
More informationCardiovascular disease is highly prevalent at all stages of
Anemia and the Heart in Chronic Kidney Disease Nadia Zalunardo* and Adeera Levin Cardiovascular disease is highly prevalent at all stages of chronic kidney disease (CKD) and is the leading cause of morbidity
More informationKidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: TheFramingham Heart Study
Kidney International, Vol. 66 (2004), pp. 2017 2021 Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: TheFramingham Heart Study
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationATHEROSCLEROTIC cardiovascular complications are the leading cause of. Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease
Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease To Decrease Plasma Adiponectin Levels Kuei-Chuan CHAN, 1 MD, Hsi-Hsien CHOU, 1 PhD, Der-Jinn WU, 1 PhD, Yi-Liang WU, 1 MD, and Chien-Ning
More informationChronic renal failure: A cardiovascular risk factor
Kidney International, Vol. 68, Supplement 99 (2005), pp. S25 S29 Chronic renal failure: A cardiovascular risk factor JOAN FORT Servicio de Nefrología, Hospital General Universitario Vall d Hebron, Universidad
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More information1. Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study Hsieh, B.P., et al. Am
More informationThe Effects of Intravenous Vitamin C Administration on hs-crp and Tumor Necrosis Factor-α Levels in Haemodialysis Patients
Functional Foods in Health and Disease 2011, 1(8):255-261 Page 255 of 261 Research Open Access The Effects of Intravenous Vitamin C Administration on hs-crp and Tumor Necrosis Factor-α Levels in Haemodialysis
More informationC-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease
Kidney International, Vol. 68 (2005), pp. 766 772 C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease VANDANA MENON, TOM GREENE, XUELEI WANG,
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationThe Impacts of Albuminuria and egfr on Cardiovascular Disease
American Journal of Health Research 2017; 5(4): 99-105 http://www.sciencepublishinggroup.com/j/ajhr doi: 10.11648/j.ajhr.20170504.12 ISSN: 2330-8788 (Print); ISSN: 2330-8796 (Online) The Impacts of Albuminuria
More informationThe cardiologist s interest in renal function
ASSESSING CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE Jeffrey Brinker, MD* ABSTRACT The manifestations of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) are
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationDevelopment of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study
J Am Soc Nephrol 14: 641 647, 2003 Development of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study JOHANNES F. E. MANN, HERTZEL C. GERSTEIN, QI-LONG YI, EVA M.
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationThe New Cardiorenal Syndrome
The New Cardiorenal Syndrome Peter Sawaya, MD, FACP, FASN Professor of Medicine Fellowship Program Director University of Kentucky The Old Cardiorenal Syndrome Heart Perfusion Na Retention Kidney What
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 5. Classification of chronic kidney disease based on evaluation of kidney function
5. Classification of chronic kidney disease based on evaluation of kidney function Date written: April 2005 Final submission: May 2005 GUIDELINES No recommendations possible based on Level I or II evidence
More informationGlomerular Filtration Rate and Coronary Artery Disease Burden in Patients with Acute Coronary Syndrome
Clin. Cardiol. 30, 464 468 (2007) Glomerular Filtration Rate and Coronary Artery Disease Burden in Patients with Acute Coronary Syndrome José Pedro L. Nunes, Maria do Sameiro Faria, J. M. Mota Garcia,
More informationThe relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population
original article http://www.kidney-international.org & 2006 International Society of Nephrology The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease
More informationMalnutrition and inflammation in peritoneal dialysis patients
Kidney International, Vol. 64, Supplement 87 (2003), pp. S87 S91 Malnutrition and inflammation in peritoneal dialysis patients PAUL A. FEIN, NEAL MITTMAN, RAJDEEP GADH, JYOTIPRAKAS CHATTOPADHYAY, DANIEL
More informationHEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI
HEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI high-flux Hemodiafiltration (HDF) Combination of two dialysis techniques, hemodialysis and hemofiltration:
More informationCardiovascular Disease and Risk Factors in Candidates for Renal Transplantation
Original Article Cardiovascular Disease and Risk Factors in Candidates for Renal Transplantation Luís Henrique Wolff Gowdak, Flávio Jota de Paula, Dante Marcelo Artigas Giorgi, Marcelo Luís Campos Vieira,
More informationHomocysteine is a sulfur-containing amino
IN THE LITERATURE Approaching the End of the Homocysteine Hype? The following is a commentary on Jamison RL, Hartigan P, Kaufman JS, et al: Effect of homocysteine lowering on mortality and vascular disease
More informationNon Conventional cardiovascular risk factors in CKD
Non Conventional cardiovascular risk factors in CKD Death rates for major cardiovascular diseases have decreased in the United States Cooper, R, Cutler, J, Desvigne-Nickens, P, et al. Circulation 2000;
More informationCardiovascular Biomarkers in CKD and in ESRD. Alberto Ortiz, MD, PhD IIS-Fundacion Jimenez Diaz Madrid, Spain
Cardiovascular Biomarkers in CKD and in ESRD Alberto Ortiz, MD, PhD IIS-Fundacion Jimenez Diaz Madrid, Spain Accelerated aging in ESRD CKD patients: CVD mortality USRDS: Levey et al. Am J Kidney Dis 1998
More informationISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world
ISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world Nutrition in Kidney Disease: How to Apply Guidelines to Clinical Practice? T. Alp
More informationCardiovascular risk in chronic kidney disease
Kidney International, Vol. 66, Supplement 92 (2004), pp. S11 S15 Cardiovascular risk in chronic kidney disease NAGESH S. ANAVEKAR and MARC A. PFEFFER Baker Cardiovascular Research Institute, Alfred Hospital,
More informationHypertension is an important global public
IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual
More informationStudy of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease
Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,
More informationStable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology
Stable Ischemic Heart Disease Ivan Anderson, MD RIHVH Cardiology Outline Review of the vascular biology of atherosclerosis Why not just cath everyone with angina? Medical management of ischemic cardiomyopathy
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationAssociation of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease
Lee et al. BMC Nephrology (2015) 16:77 DOI 10.1186/s12882-015-0068-7 RESEARCH ARTICLE Open Access Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease
More informationNovel Markers of Arterial Dysfunction
혈관연구회창립심포지움, 3 월 3 일, 2005 Novel Markers of Arterial Dysfunction Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon Medical School Incheon, Korea Atherosclerosis: A progressive process PHASE I: Initiation
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More information